7-Ethoxyrosmanol alleviates hyperglycemia-induced vascular endothelial dysfunction by regulating FBXL7 expression

Area of Science:

• Biomedical Science
• Pharmacology
• Cell Biology

Background:

• Current hyperglycemia treatments are insufficient, leading to endothelial dysfunction.
• Hyperglycemia-induced endothelial dysfunction is a significant complication requiring novel therapeutic approaches.

Purpose of the Study:

• To investigate the potential of 7-Ethoxyrosmanol (7ERM) as a therapeutic agent for hyperglycemia-induced endothelial dysfunction.
• To elucidate the role of F-box/LRR-repeat protein 7 (FBXL7) in the protective mechanism of 7ERM.

Main Methods:

• Human umbilical vein endothelial cells (HUVECs) were exposed to high glucose and varying doses of 7ERM.
• Cell injury, inflammation, reactive oxygen species (ROS) production, and FBXL7 expression were measured.
• FBXL7 was manipulated via siRNA knockdown and plasmid overexpression to assess its role.

Main Results:

• 7ERM treatment mitigated high glucose-induced cell injury, inflammation, and ROS production in HUVECs.
• High glucose increased FBXL7 expression, which was inhibited by 7ERM.
• FBXL7 knockdown protected against high glucose-induced cell injury, while its overexpression reduced 7ERM's protective effects.

Conclusions:

• 7-Ethoxyrosmanol (7ERM) effectively attenuates hyperglycemia-induced endothelial dysfunction in HUVECs.
• The protective mechanism involves the regulation of F-box/LRR-repeat protein 7 (FBXL7) expression.
• 7ERM demonstrates potential as a novel therapeutic drug for hyperglycemia treatment.